Bleomycin
drugOn this page
Also known as BlenamaxBleoBleocinBleomicinaBleomycin hexalBleomycineBleomycinsNSC-125066blenoxaneBleomycin (BLEO)BLM (bleomycin)Bleomycin A2
Summary
Bleomycin (CHEMBL6067492) is an approved unknown (ATC L01DC01); indicated across 22 conditions including neoplasm and testicular cancer.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Unknown
- ATC class: L01DC01
- Indications: 22 conditions
- Clinical trials: 72
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL6067492 |
| Name | Bleomycin |
| Type | Unknown |
| Max phase | 4 |
| ATC | L01DC01 |
Also known as: Blenamax, Bleo, Bleocin, Bleomicina, Bleomycin, Bleomycin hexal, Bleomycine, Bleomycins, NSC-125066, blenoxane, Bleomycin (BLEO), BLM (bleomycin)
Parent form; salt/anhydrous children: CHEMBL6067493
Targets
Targets
Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Aspartyl/asparaginyl beta-hydroxylase.
Bioactivity
ChEMBL activities: 4 potent at pChembl ≥ 5 of 4 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| ASPH | 5.83 | IC50 | 1470 | nM | CHEMBL_ACT_22416325 |
| ASPH | 5.78 | IC50 | 1650 | nM | CHEMBL_ACT_22416361 |
| ASPH | 5.7 | IC50 | 1990 | nM | CHEMBL_ACT_22416349 |
| ASPH | 5.42 | IC50 | 3810 | nM | CHEMBL_ACT_22416337 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
22 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| neoplasm | 4 | MONDO:0005070 | EFO:0000616 |
| testicular cancer | 3 | MONDO:0005447 | EFO:0004281 |
| seminoma | 3 | MONDO:0003001 | MONDO:0003001 |
| HIV infectious disease | 3 | MONDO:0005109 | EFO:0000180 |
| Hodgkins lymphoma | 3 | MONDO:0004952 | EFO:0000183 |
| diffuse large B-cell lymphoma | 3 | MONDO:0018905 | EFO:0000403 |
| lymphoma | 3 | MONDO:0005062 | EFO:0000574 |
| pericardial effusion | 3 | MONDO:0001370 | MONDO:0001370 |
| ovarian cancer | 3 | MONDO:0008170 | MONDO:0008170 |
| head and neck squamous cell carcinoma | 2 | MONDO:0010150 | EFO:0000181 |
| peripheral T-cell lymphoma, not otherwise specified | 2 | MONDO:0004964 | EFO:0000211 |
| germ cell tumor | 2 | MONDO:0005040 | EFO:0000514 |
| head and neck cancer | 2 | MONDO:0005627 | EFO:0006859 |
| central nervous system neoplasm | 2 | MONDO:0006130 | EFO:1000158 |
| rectal cancer | 2 | MONDO:0006519 | EFO:1000657 |
| vulva cancer | 2 | MONDO:0001528 | MONDO:0001528 |
| lymphedema | 2 | MONDO:0019297 | MONDO:0019313 |
| gastric neoplasm | 1 | MONDO:0021085 | MONDO:0001056 |
4 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 72.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 30 |
| PHASE3 | 21 |
| Not specified | 8 |
| PHASE4 | 6 |
| PHASE1 | 5 |
| PHASE1/PHASE2 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06647342 | PHASE4 | RECRUITING | The Effect of Reduced Bleomycin in Electrochemotherapy Treatment |
| NCT07197541 | PHASE4 | NOT_YET_RECRUITING | A Self-controlled Study of Bleomycin and Pingyangmycin Injection in the Treatment of Plantar Warts |
| NCT01347294 | PHASE4 | UNKNOWN | Compare Two Different Sclerosing Agents in the Treatment of Venous Malformations |
| NCT03477448 | PHASE4 | UNKNOWN | The Efficacy of Intra-lesional Bleomycin Versus Intra-lesional Purified Protein Derivative in Treatment of Palmoplantar Warts |
| NCT04046679 | PHASE4 | UNKNOWN | Bleomycin Infusion (MMP®) to Repigment Achromic Scars |
| NCT04582305 | PHASE4 | UNKNOWN | Bleomycin Jet Injections in Keloids |
| NCT02429687 | PHASE3 | RECRUITING | TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors |
| NCT02429700 | PHASE3 | RECRUITING | TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors |
| NCT02661503 | PHASE3 | ACTIVE_NOT_RECRUITING | HD21 for Advanced Stages |
| NCT04638790 | PHASE3 | RECRUITING | First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1) |
| NCT04685616 | PHASE3 | RECRUITING | Brentuximab Vedotin in Early Stage Hodgkin Lymphoma |
| NCT00002835 | PHASE3 | COMPLETED | Combination Chemotherapy in Treating Patients With Lymphoma |
| NCT00003389 | PHASE3 | COMPLETED | Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin’s Lymphoma |
| NCT00038558 | PHASE3 | COMPLETED | Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin’s Disease Receiving ABVD Chemotherapy |
| NCT00135499 | PHASE3 | TERMINATED | R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma |
| NCT00264953 | PHASE3 | COMPLETED | HD11 for Intermediate Stages |
| NCT00265018 | PHASE3 | COMPLETED | HD10 for Early Stages |
| NCT00265031 | PHASE3 | COMPLETED | HD12 for Advanced Stages |
| NCT00577993 | PHASE3 | COMPLETED | Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients |
| NCT00736320 | PHASE3 | UNKNOWN | HD16 for Early Stage Hodgkin Lymphoma |
| NCT01251107 | PHASE3 | COMPLETED | Study Comparing ABVD vs BEACOPP in Advanced Hodgkin’s Lymphoma |
| NCT01356680 | PHASE3 | COMPLETED | HD17 for Intermediate Stage Hodgkin Lymphoma |
| NCT01435018 | PHASE3 | COMPLETED | Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS |
| NCT01659099 | PHASE3 | TERMINATED | GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma |
| NCT01712490 | PHASE3 | COMPLETED | A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma |
| NCT03018626 | PHASE3 | UNKNOWN | R-ACVBP and DA-EPOCH-R in Patients With Non-GCB DLBCL |
| NCT03159897 | PHASE3 | COMPLETED | FIL Study on ABVD DD-DI as Upfront Therapy in HL. |
| NCT01873326 | PHASE2 | ACTIVE_NOT_RECRUITING | Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors |
| NCT03033914 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL) |
| NCT03407144 | PHASE2 | ACTIVE_NOT_RECRUITING | Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) |
| NCT03712202 | PHASE2 | ACTIVE_NOT_RECRUITING | Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma |
| NCT03755804 | PHASE2 | ACTIVE_NOT_RECRUITING | Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 |
| NCT05395962 | PHASE2 | RECRUITING | Electrochemotherapy With Carboplatinum Plus Bleomycin Versus Bleomycin Alone in Vulvar Cancer |
| NCT06144736 | PHASE2 | RECRUITING | PRIMETEST II - Clinical Stage II A/B Seminoma Treated With RA-RPLND |
| NCT06437158 | PHASE2 | RECRUITING | Use of Bleomycin in the Sclerotherapy of Lymphatic Malformations for Pediatric Patients |
| NCT06715592 | PHASE2 | ACTIVE_NOT_RECRUITING | ECT STUDY High-grade or Initially Invasive Vulva - GinOnc-ECT Study |
| NCT06718192 | PHASE1/PHASE2 | RECRUITING | A Randomized Controlled Trial to Evaluate the Effectiveness of Bleomycin and Cryotherapy in Treating Plantar Warts. |
| NCT07320001 | PHASE2 | NOT_YET_RECRUITING | Injection Sclerotherapy With Bleomycin VS Doxycycline in Patients With Lymphatic Malformations |
| NCT00006916 | PHASE2 | TERMINATED | Radiation Therapy Followed by Bleomycin in Treating Adult Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme |
| NCT00026208 | PHASE2 | COMPLETED | Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin’s Lymphoma |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).